Tirzepatide targets GIP + GLP-1. Retatrutide adds glucagon receptor activation to increase basal energy expenditure.
| Feature / Metric | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor Targets | Dual (GIP + GLP-1) | Triple (GIP + GLP-1 + Glucagon) |
| FDA Status | Approved (Zepbound) | Phase 3 Clinical Trials |
| Starting Dose | 2.5 mg / week | 2.0 mg / week |
| Energy Expenditure Impact | Moderate | High (via Glucagon stimulation) |
Access chemical profile, half-life parameters, and U-100 reconstitution calculator.
Access chemical profile, half-life parameters, and U-100 reconstitution calculator.
Tirzepatide targets GIP + GLP-1. Retatrutide adds glucagon receptor activation to increase basal energy expenditure. In preclinical and clinical research trials, comparing receptor affinity, half-life clearance, and synthesis purity standards is critical for determining appropriate research protocols.
In scientific literature, certain peptide pairs (such as BPC-157 + TB-500, or CJC-1295 + Ipamorelin) exhibit complementary signaling pathways and are frequently studied together in stack protocols.
